A Single Center, Retrospective Analysis of Prognosis in Non-small Cell Lung Cancer Patients with Peritoneal Carcinomatosis.
10.3779/j.issn.1009-3419.2019.03.04
- Author:
Baoshan CAO
1
;
Yan'e LIU
1
;
Wencheng YIN
1
;
Qian LI
1
;
Li LIANG
1
Author Information
1. Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China.
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Overall survival;
Peritoneal carcinomatosis
- MeSH:
Adult;
Aged;
Carcinoma, Non-Small-Cell Lung;
diagnosis;
pathology;
therapy;
Female;
Humans;
Lung Neoplasms;
diagnosis;
pathology;
therapy;
Male;
Middle Aged;
Peritoneal Neoplasms;
secondary;
Prognosis;
Retrospective Studies
- From:
Chinese Journal of Lung Cancer
2019;22(3):143-150
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Peritoneal carcinomatosis is a rare clinical event in lung cancer and the prognosis is very poor. There are limited data on what factors predict peritoneal progression and affect the outcome. The aim of this study is to investigate investigate the factors associated with peritoneal carcinomatosis.
METHODS:The patients with non-small cell lung cancer (NSCLC) from the Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital were eligible for retrospective analysis between August 2010 and August 2018. Clinical factors such as age, gender, histology, pleural effusion and gene mutations with epidermal growth factor receptor/anaplastic lymphoma kinase/ROS proto-oncogene 1 receptor tyrosine kinase (EGFR/ALK/ROS1) were analyzed. Overall survival (OS) was calculated by the Kaplan-Meier method.
RESULTS:1.44% (12/836) patients in this study developed peritoneal carcinomatosis and 12 patients with adenocarcinoma had metachronous NSCLC diagnosis and PC. Malignant pleural effusion rates at baseline and at PC diagnosis were separately 50% (6/12) and 100.0% (12/12). Among the 12 patients, 9 patients harbored EGFR/ALK/ROS1 mutation. The outcome of patients with EGFR/ALK/ROS1 mutation was significantly better than that of patients without EGFR/ALK/ROS1 mutation, the mOS1 and mOS2 were separately 26.0 months and 6.0 months versus 10.0 months and 1.5 months (P<0.05). The mOS2 of patients with aggressive treatment after PC diagnosis was 6.0 months, significantly better than 1.0 month of patients with best supportive care (P<0.05). The mOS2 of the patients with angiogenesis inhibitors based-treatment after PC diagnosis was 8.5 months, significantly longer than that of patients with other treatments (P<0.05).
CONCLUSIONS:Adenocarcinoma and malignant pleural effusion are highly associated with peritoneal carcinomatosis in patients with advanced NSCLC. Aggressive treatment for lung cancer with PC is encouraged when possible. More patients with PC may benefit from the treatment strategies with angiogenesis inhibitors. Further prospective trials are urgently needed.
